Real-world data of first-line treatment with aumolertinib for elderly EGFR plus NSCLC patients

被引：0
|
作者：
Zhang, H. [1 ]
Cun, F. S. [1 ]
机构：
[1] Nanjing Chest Hosp, Resp Med, Nanjing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.409
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
371P
引用
收藏
页码：S1586 / S1587
页数：2
相关论文
共 50 条
  • [41] Paclitaxel Liposome Combined with Immunotherapy in the First-Line Treatment of Advanced NSCLC: A Multicenter Real-World Study
    Jiang, L.
    Zheng, D.
    Ni, J.
    Ding, H.
    Zhao, Y.
    Heng, W.
    Shang, Y.
    Cai, X.
    Yan, J.
    Wang, J.
    Guo, J.
    Tan, X.
    Hong, X.
    Zhang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S248 - S249
  • [42] Real-world outcomes in advanced melanoma patients treated with first-line nivolumab plus ipilimumab
    Kozak, Katarzyna
    Teterycz, Pawel
    Galus, Lukasz
    Mackiewicz, Jacek
    Galwas-Kliber, Katarzyna
    Kaminska-Winciorek, Grazyna
    Brandys, Piotr
    Cybulska-Stopa, Bozena
    Kempa-Kaminska, Natasza
    Zietek, Marcin
    Zubrowska, Justyna
    Dziura, Robert
    Dembinski, Mateusz
    Bereza, Michal
    Czarnecka, Anna Malgorzata
    Rutkowski, Piotr
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] Real-world clinical outcomes in Chinese patients with EGFR-mutated NSCLC progressed from first-line EGFR-TKI: A prospective multicenter study
    Tian, Panwen
    Wu, Lin
    Zhou, Chengzhi
    Tan, Jie
    Wang, Ke
    Luo, Feng
    Liu, Yongmei
    Guo, Yubiao
    Li, Yinyin
    Liu, Zhe
    Gong, Youling
    Wang, Yongsheng
    Li, Weimin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] Dacomitinib Versus Gefitinib for First-Line Treatment of Advanced EGFR plus NSCLC in Japanese Patients (ARCHER 1050)
    Nakagawa, K.
    Ohyanagi, F.
    Kato, T.
    Takahashi, T.
    Kaneda, H.
    Nogami, N.
    Niho, S.
    Yamamoto, N.
    Fujita, Y.
    Zhang, H.
    Sbar, E.
    Wang, H.
    Linke, R.
    Tsuji, F.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2229 - S2230
  • [45] Real-world treatment patterns and outcomes among patients with BRAF plus metastatic melanoma refractory to first-line immunotherapy
    Truong, T. G.
    Chandra, S.
    Connolly, L.
    Shah, R.
    Byrne, C.
    Tang, J.
    Eroglu, Z.
    ANNALS OF ONCOLOGY, 2023, 34 : S673 - S673
  • [46] Real-world treatment modification of first-line axitinib plus pembrolizumab in patients with metastatic renal cell carcinoma (mRCC)
    Zakharia, Y.
    Thomaidou, D.
    Li, B.
    Siu, G.
    Levin, R.
    Vlahiotis, A.
    Zanotti, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S1423 - S1424
  • [47] Treatment patterns of EGFR mt plus NSCLC IV patients: real world data of the NOWEL network
    Roeper, J.
    Falk, M.
    Schatz, S.
    Tiemann, M.
    Wesseler, C.
    Wiest, G. H.
    Ukena, D.
    Sackmann, S.
    Griesinger, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 132 - 132
  • [48] Real-World First-Line Treatment Patterns Among US Carcinoid Syndrome Patients
    Sun, Gordon H.
    Neary, Maureen P.
    Chang, Eunice
    Broder, Michael S.
    PANCREAS, 2015, 44 (02) : 359 - 360
  • [49] Real-world data on treatment patterns and survival among ALK plus NSCLC patients in Japan
    Nosaki, Kaname
    Toyozawa, Ryo
    Taguchi, Kenichi
    Edagawa, Makoto
    Shimamatsu, Shin-Ichiro
    Toyokawa, Goji
    Hirai, Fumihiko
    Yamaguchi, Masafumi
    Takeda, Yoko
    Seto, Takashi
    Takenoyama, Mitsuhiro
    Ichinose, Yukito
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] First-line alectinib vs. brigatinib in advanced metastatic NSCLC with ALK rearrangement: Real-world data
    Jeon, Y. K.
    Park, S.
    Jung, H. A.
    Sun, J-M.
    Lee, S-H.
    Ahn, J. S.
    Ahn, M-J.
    ANNALS OF ONCOLOGY, 2023, 34
12345